# Radiotherapy in Combination With TTI-101 in Borderline Resectable and Locally Advanced Pancreatic Ductal Adenocarcinoma

> **NCT06141031** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **Washington University School of Medicine** · enrollment: 5 (actual)

## Conditions studied

- Pancreatic Cancer

## Interventions

- **DRUG:** TTI-101
- **RADIATION:** Stereotactic body radiation therapy

## Key facts

- **NCT ID:** NCT06141031
- **Lead sponsor:** Washington University School of Medicine
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2024-01-16
- **Primary completion:** 2029-06-30
- **Final completion:** 2029-06-30
- **Target enrollment:** 5 (ACTUAL)
- **Last updated:** 2026-05-12

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06141031

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06141031, "Radiotherapy in Combination With TTI-101 in Borderline Resectable and Locally Advanced Pancreatic Ductal Adenocarcinoma". Retrieved via MORVS 2026-10-15 from https://api.morvs.ai/clinical/NCT06141031. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*